Arrowstreet Capital
RVNC

Arrowstreet Capital’s Revance Therapeutics, Inc. RVNC Stock Holding History

Arrowstreet Capital’s Portfolio RVNC Stock Details RVNC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-145,080
Closed -$753K – 2027
2024
Q3 		$753K Buy
+145,080
New +$721K ﹤0.01% 1451
2020
Q4 		– Sell
-108,195
Closed -$2.72M – 2590
2020
Q3 		$2.72M Buy
+108,195
New +$2.84M ﹤0.01% 1431
2015
Q1 		– Sell
-12,161
Closed -$206K – 1257
2014
Q4 		$206K Buy
+12,161
New +$212K ﹤0.01% 1184

Other funds holding RVNC

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BCM
Beryl Capital Management Redondo Beach, California $110M AUM 317.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
OBAM
ODDO BHF Asset Management Paris, France $2.54B AUM 41.83% 1-Year Est. Return
Fidelity International
Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
Squarepoint
Squarepoint New York $85.1B AUM 20.93% 1-Year Est. Return
MF
Magnetar Financial Evanston, Illinois $9.84B AUM 190.63% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AAM
Alpine Associates Management Palm Beach, Florida $1.6B AUM 93.19% 1-Year Est. Return

Arrowstreet Capital's RVNC Position: Q4 2024 in Review

Arrowstreet Capital sold out of Revance Therapeutics, Inc. (RVNC) in Q4 2024, closing a stake of 145,080 shares — an estimated $753K sold.

Arrowstreet Capital first reported a position in RVNC in Q4 2014 and held it in 3 quarters. The position peaked at $2.72M in Q3 2020. 173 funds tracked by Wall St. Rank hold RVNC as of Q4 2024.

  • Arrowstreet Capital reported no remaining Revance Therapeutics, Inc. position as of Q4 2024 after selling out during the quarter.
  • Arrowstreet Capital sold 145,080 Revance Therapeutics, Inc. shares in Q4 2024, an estimated $753K.
  • Arrowstreet Capital first reported a position in Revance Therapeutics, Inc. in Q4 2014 and held it in 3 quarters.
  • Arrowstreet Capital's Revance Therapeutics, Inc. position peaked at $2.72M in Q3 2020.
  • 173 funds tracked by Wall St. Rank held Revance Therapeutics, Inc. as of Q4 2024.

Based on Arrowstreet Capital's 13F filing for Q4 2024, filed 12 Feb 2025.